메디톡스

086900KOSDAQ기초 의약물질 제조업

52.1 / 100

Reference Date: 2026-07-24

Financial Score18.5 / 40

News Sentiment19.6 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but Operating Profit metrics are weak. Declined 7.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Medytox specializes in the research, development, manufacturing, and sales of biopharmaceuticals using botulinum toxin type A, with flagship products such as Meditoxin® and Innotox®. In 2024, its key pharmaceutical products accounted for approximately 84% of consolidated revenue, and the company has expanded exports to over 30 countries.

Number of Employees

753people

Average Salary

64.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

30.16Industry Average 25.443.0Point

Higher than industry avg (caution)

PBR

1.15Industry Average 1.264.0Point

In line with industry avg

ROE

3.39Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

4.99Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.8% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.0% (improving, 3yr)

Detailed News Sentiment

17 totalPositive 14Neutral 2Negative 1Average Sentiment Score 78.5

Positive
비만치료 열풍 업고…‘뉴비쥬’ 초반 돌풍[바이오리더스클럽]
메디톡스의 체중 감량 주사제 '뉴비쥬'가 출시 후 빠른 성장세를 보이며 연간 매출 목표 달성에 근접, 긍정적인 시장 반응을 이끌고 있다.
Positive
메디톡스 "신규 학술교육 프로그램 첫행사 개최"
메디톡스가 신규 학술교육 프로그램을 성공적으로 개최하여 전문성 강화에 기여함.
Neutral
[바이오스냅] GC녹십자의료재단, ISO 45001 인증 획득
GC녹십자의료재단의 ISO 45001 인증 획득 소식은 관련 의료 및 안전 관리 분야에 긍정적 영향을 미칠 수 있으나, 메디톡스 주식에 직접적인 영향은 제한적입니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 71,500Won52-week high 151,90052-week low 68,300

1-month return1.0Point

1m -7.38% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-07
Neutral[기재정정]주식소각결정 (상환전환우선주)2026-06-30
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-26
Neutral주식등의대량보유상황보고서(일반)2026-06-26